Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Eosinophilic Granulomatosis with Polyangiitis - Market Insight, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.
The report delivers the most comprehensive analysis to date of this ultra-rare vasculitic condition, its epidemiology, treatment landscape, and evolving commercial opportunity. This essential report equips healthcare industry professionals, pharma executives, R&D strategists, and decision-makers with the data-driven insights needed to inform product strategy, investment decision-making, and competitive differentiation
Spanning the 7 major markets (7MM) – the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan – this authoritative market analysis combines historical and projected epidemiological data (2020–2034) with detailed assessments of current and emerging therapies, treatment paradigms, patient populations, market access, reimbursement challenges, and forecasting models through 2034.
For years, corticosteroids and non-specific immunosuppressants like cyclophosphamide were the only options for EGPA management. Today, the market is characterized by a shift toward targeted biologics that offer vital steroid-sparing benefits.
The report delivers deep-dive chapters on marketed drugs, featuring:
- NUCALA (mepolizumab): The first FDA-approved targeted therapy for EGPA, which has demonstrated a 50% reduction in glucocorticoid use in clinical settings.
- FASENRA (benralizumab): A recent entrant with 2024 approvals in the US and EU, showing nearly 60% remission rates in the MANDARA trial.
Beyond current leaders, the report evaluates the "Probability of Success" for emerging therapies, providing an attribute-based analysis of safety, efficacy, and order of market entry.
Key Highlights
- Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a rare form of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis affecting small to medium-sized blood vessels. This systemic condition can lead to life-threatening damage across multiple organ systems.
- EGPA is classified as an ultra-rare disease in the United States, with approximately 5,000 cases. In Germany, its prevalence is estimated at 2 cases per million, according to secondary data analysis.
- The increase in EGPA cases is attributed to advances in diagnostic techniques, greater clinical awareness, broader use of ANCA testing, and rising incidence of asthma and eosinophilic disorders.
- Management of EGPA involves FDA-approved biologics like NUCALA (mepolizumab, GSK) and FASENRA (benralizumab, AstraZeneca), which target IL-5 to control eosinophilic activity. Corticosteroids and immunosuppressants are also used to reduce inflammation and prevent relapses.
- Numerous companies are developing therapies for EGPA, including NS Pharma (Nippon Shinyaku) with NS-229 and GSK with depemokimab, aiming to meet critical unmet clinical needs. Regulatory approval of these therapies will enhance EGPA treatment options and stimulate market growth.
The report titled "Eosinophilic Granulomatosis with Polyangiitis (EGPA) - Market Insights, Epidemiology, and Market Forecast - 2034" provides comprehensive analysis covering historical and projected epidemiological data, patient demographics, diagnosis processes, prescription patterns, and expected market developments in the United States, EU4, the United Kingdom, and Japan from 2020 to 2034.
The report evaluates existing treatment practices and identifies potential business prospects for enhancing therapies or interventions, enabling stakeholders to make informed decisions about product development and marketing strategies.
Why this report matters
- Strategic Market Forecasting: Gain precise CAGR projections and market dynamics for the 7MM through 2034 to de-risk investment decisions.
- Epidemiology Insights: Access detailed patient pool data and prevalence trends across the United States, Germany, France, Italy, Spain, the UK, and Japan.
- Competitive Intelligence: Identify strong upcoming players and analyze class-wise potential of emerging therapies to stay ahead of market shifts.
- Unmet Need Identification: Leverage Key Opinion Leader (KOL) insights to understand gaps in relapse prevention and tailored treatments for ANCA subtypes.
- Market Access & Reimbursement: Navigate country-specific healthcare systems, reimbursement policies, and barriers to accessibility for high-cost therapies.
The findings in this report are validated by insights from over 20+ KOLs and Subject Matter Experts (SMEs) from prestigious institutions, including Wilson Case Western University (US), the University of Tübingen (Germany), and Kochi Medical School (Japan). These experts highlight a critical transition: while biologics have revolutionized care, the industry still faces a high demand for therapies that eliminate long-term steroid dependence and prevent organ damage.
Reasons to Buy
- The report aids in crafting business strategies by understanding market trends and treatment dynamics.
- Offers insights into patient burden and the evolving landscape of EGPA diagnosis.
- Facilitates understanding of market opportunities across geographies and growth potential.
- Provides competitive insights into emerging therapies and market strategies.
- Highlights market access policies, reimbursement barriers, and patient assistance program
A selection of companies mentioned in this report includes, but is not limited to:
- GSK
- AstraZeneca
- NS Pharma
For more information about this report visit https://www.researchandmarkets.com/r/grkr6a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
